{"id":"consolidation-cycle-a6","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3652563","moleculeType":"Small molecule","molecularWeight":"435.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-drug consolidation chemotherapy cycle administered as part of a structured ALL treatment protocol. Consolidation cycles are designed to target and eliminate leukemic blasts that may remain after induction therapy, using combinations of cytotoxic agents to prevent relapse and improve long-term survival outcomes in pediatric patients.","oneSentence":"Consolidation Cycle A6 is a chemotherapy regimen used in pediatric acute lymphoblastic leukemia (ALL) treatment to eliminate residual leukemic cells after initial induction therapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:28.455Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL) in pediatric patients — consolidation phase treatment"}]},"trialDetails":[{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96},{"nctId":"NCT02600897","phase":"PHASE1, PHASE2","title":"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-24","conditions":"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":114},{"nctId":"NCT03390387","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2015-11","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":4000},{"nctId":"NCT01183884","phase":"PHASE2","title":"3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Neuroblastoma","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Consolidation Cycle A6","genericName":"Consolidation Cycle A6","companyName":"Nationwide Children's Hospital","companyId":"nationwide-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Consolidation Cycle A6 is a chemotherapy regimen used in pediatric acute lymphoblastic leukemia (ALL) treatment to eliminate residual leukemic cells after initial induction therapy. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients — consolidation phase treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}